DaVita Inc.
Financials
Valuation Metrics
DaVita Inc.'s Market Cap is $11.80B. At end of 2025 it was $9.78B. Ranked #834 of 3,121 in US market (top 27%), #573 of 1,658 on NYSE (top 35%), #55 of 205 in Health Care Equipment & Services (top 27%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $11.80B | US#834/3,121 Sec#55/205 |
| Revenue | $14.01B | US#440/3,121 Sec#30/205 |
| Net Income | $847M | US#617/3,121 Sec#34/205 |
| Total Assets | $17.71B | US#677/3,121 Sec#31/205 |
| Net Assets | $-765M | US#3,038/3,121 Sec#201/205 |
| Employees | 78,000 | US#158/3,121 Sec#11/205 |
| Value | ||
| P/E | 13.92x | US#693/3,121 Sec#12/205 |
| PEG | 10.39x | US#1,248/3,121 Sec#69/205 |
| P/S | 0.84x | US#582/3,121 Sec#42/205 |
| EV/EBITDA | 7.93x | US#489/3,121 Sec#14/205 |
| FCF Yield | 13.64% | US#316/3,121 Sec#11/205 |
| Profitability | ||
| ROA | 4.79% | US#1,088/3,121 Sec#71/205 |
| Op. Margin | 15.06% | US#1,215/3,121 Sec#44/205 |
| Revenue Growth | 6.45% | US#1,660/3,121 Sec#119/205 |
| Earnings Growth | 1.34% | US#1,274/3,121 Sec#70/205 |
| Financial Health | ||
| Total Debt | $10.78B | US#393/3,121 Sec#21/205 |
| FCF | $1.61B | US#429/3,121 Sec#28/205 |
| Cash | $669M | US#894/3,121 Sec#47/205 |
| Current Ratio | 1.47x | US#1,707/3,121 Sec#150/205 |
| Net Debt/EBITDA | 3.66x | US#1,769/3,121 Sec#115/205 |
| Dividend | ||
| Div. Yield | 1.27% | US#1,195/3,121 Sec#21/205 |
| Performance | ||
| 1Y Return | 41.17% | US#663/3,121 Sec#54/205 |
| 1M Return | 3.71% | US#632/3,121 Sec#72/205 |
| From 52W High | -25.71% | US#1,843/3,121 Sec#128/205 |
| 1Y MDD | -27.86% | US#1,264/3,121 Sec#48/205 |
| Trading | ||
| Volume | 737,574 shares | US#1,261/3,121 Sec#75/205 |
| Trading Value | $135M | US#424/3,121 Sec#37/205 |
| Per Share | ||
| EPS | $13.20 | US#184/3,121 Sec#15/205 |
| BPS | $-11.92 | US—/3,121 Sec—/205 |
Company Info
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.